Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) Other Non Operating Income (2019 - 2025)

Historic Other Non Operating Income for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to $16.5 million.

  • BridgeBio Pharma's Other Non Operating Income rose 81602.67% to $16.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year increase of 15083.63%. This contributed to the annual value of -$26.6 million for FY2024, which is 25308.0% down from last year.
  • As of Q3 2025, BridgeBio Pharma's Other Non Operating Income stood at $16.5 million, which was up 81602.67% from $6.5 million recorded in Q2 2025.
  • Over the past 5 years, BridgeBio Pharma's Other Non Operating Income peaked at $28.3 million during Q4 2021, and registered a low of -$26.6 million during Q1 2024.
  • For the 5-year period, BridgeBio Pharma's Other Non Operating Income averaged around $1.2 million, with its median value being $1.6 million (2023).
  • Its Other Non Operating Income has fluctuated over the past 5 years, first crashed by 770000.0% in 2021, then surged by 113607.59% in 2025.
  • BridgeBio Pharma's Other Non Operating Income (Quarter) stood at $28.3 million in 2021, then plummeted by 83.88% to $4.6 million in 2022, then surged by 377.59% to $21.8 million in 2023, then plummeted by 91.75% to $1.8 million in 2024, then skyrocketed by 816.03% to $16.5 million in 2025.
  • Its last three reported values are $16.5 million in Q3 2025, $6.5 million for Q2 2025, and -$21.2 million during Q1 2025.